Gara Jalqabaatti › Myeloma Baay’ee › New York › New York City
Qorannoo klinikaalii Myeloma Baay’ee New York City, NY keessatti
Qorannoo 60 Myeloma Baay’ee f New York City fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia
Namoota walitti qabaa jiraSadarkaa 2
- Mount Sinai Hospital, New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
Namoota walitti qabaa jira
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Limited-duration Teclistamab
Namoota walitti qabaa jiraSadarkaa 2
- Columbia University, New York
A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
Namoota walitti qabaa jiraSadarkaa 2
- Memorial Sloan Kettering Cancer Center (All protocol activities), New York
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, New York
- Research Site, New York
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Namoota walitti qabaa jiraSadarkaa 1
- Icahn School of Medicine at Mt. Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1/2
- Memorial Sloan Kettering Cancer Center Mskcc, New York
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Namoota walitti qabaa jiraSadarkaa 4
- Mount Sinai Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 3
- Mount Sinai Chelsea, New York
- Laura and Isaac Perlmutter Cancer Center NYU ACC, New York
- Icahn School of Medicine at Mount Sinai, New York
- fi 1 dabalataa
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 3
- NYU Langone Health Manhattan, New York
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Namoota walitti qabaa jiraSadarkaa 3
- Memorial Sloan Kettering Cancer Center, New York
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
Namoota walitti qabaa jiraSadarkaa 1
- Research Site, New York
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Namoota walitti qabaa jiraSadarkaa 2
- Icahn School of Medicine at Mt. Sinai, New York
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Namoota walitti qabaa jiraSadarkaa 3
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
- Memorial Sloan Kettering Cancer Center-Main Campus, New York
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1/2
- Memorial Sloan Kettering, New York
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 2
- Mount Sinai Medical Center, New York
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 3
- Perlmutter Cancer Center at NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
- Weill Cornell Medical College, New York
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1/2
- Tisch Cancer Institute at Mount Sinai, New York
- Memorial Sloan-Kettering Cancer Center, New York
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Manhattan Eye, Ear, and Throat Hospital, New York
- Staten Island University Hospital, New York
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Namoota walitti qabaa jiraSadarkaa 2/3
- Icahn School of Medicine at Mount Sinai /ID# 277844, New York
- Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 277946, New York
- Weill Cornell Medicine Myeloma Center /ID# 278216, New York
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Namoota walitti qabaa jiraSadarkaa 3
- David H. Koch Center for Cancer Care, New York
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1/2
- Mount Sinai, The Tisch Cancer Instutute, New York
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Namoota walitti qabaa jiraSadarkaa 3
- Weill Cornell Medical College, New York
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 2
- Icahn School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
Namoota walitti qabaa jiraSadarkaa 2
- Icahn School of Medicine at Mount Sinai, New York
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Namoota walitti qabaa jiraSadarkaa 1/2
- Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 271214, New York
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
- Icahn School of Medicine at Mount Sinai，The Tisch Cancer Institute, New York
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Namoota walitti qabaa jiraSadarkaa 3
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
- Memorial Sloan Kettering Cancer Center - Main Campus, New York
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1/2
- Research Site, New York
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1
- Memorial Sloan-Kettering Cancer Center, New York
A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Namoota walitti qabaa jiraSadarkaa 1/2
- Research Site, New York
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, New York
- Research Site, New York
- Research Site, New York
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Namoota walitti qabaa jiraSadarkaa 1
- Memorial Sloan Kettering Cancer Center, New York
Delayed Toxicities Post-CAR-T
Namoota walitti qabaa jiraQorannoo ilaalaa
- Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy
Namoota walitti qabaa jiraQorannoo ilaalaa
- Weill Cornell Medical Center (Data Analysis Only), New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 2
- The Tisch Cancer Institute/Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1/2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Namoota walitti qabaa jiraSadarkaa 1/2
- Mount Sinai - The Tisch Cancer Institute /ID# 272470, New York
- Weill Cornell Medical College /ID# 272517, New York
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1
- Laura and Isaac Perlmutter Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1
- Mt Sinai /ID# 251166, New York
- Memorial Sloan Kettering Cancer Center-Koch Center /ID# 251167, New York
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Namoota walitti qabaa jiraSadarkaa 1
- Weill Cornell Medicine/New York Presbyterian Hospital, New York
- New York Presbyterian Hospital Columbia University Medical Center, New York
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Namoota walitti qabaa jiraSadarkaa 2
- Weill Cornell Medical Center (Data Collection Only), New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
The Ambient Light Multiple Myeloma Study
Namoota walitti qabaa jira
- Icahn Schoool of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Namoota walitti qabaa jiraSadarkaa 3
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
Namoota walitti qabaa jira
- Icahn School of Medicine at Mount Sinai, New York
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Namoota walitti qabaa jiraSadarkaa 3
- Mount Sinai Medical Center - 2, New York
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Namoota walitti qabaa jiraSadarkaa 1/2
- Perlmutter Cancer Center, New York
- Columbia University _ New York Presbyterian, New York
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1
- Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 270282, New York
A Dietary Study for People With Multiple Myeloma
Namoota walitti qabaa jira
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Namoota walitti qabaa jiraSadarkaa 3
- GSK Investigational Site, New York
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1/2
- Icahn School of Medicine at Mount Sinai, New York
Study of CAR-T Therapy in Older Patients
Namoota walitti qabaa jiraQorannoo ilaalaa
- Memorial Sloan Kettering Cancer Center, New York
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1
- Icahn School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
Namoota walitti qabaa jiraSadarkaa 2
- Memorial Sloan Kettering Cancer Center, New York
In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
Namoota walitti qabaa jiraSadarkaa jalqabaa 1
- Memorial Sloan Kettering Cancer Center, New York
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
- Memorial Sloan Kettering Cancer Center, New York
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1
- Icahn School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1/2
- Memorial Sloan Kettering Cancer Center, New York
Qorannoo Myeloma Baay’ee magaalota biroo keessatti
- Boston, MAQorannoo 42
- Atlanta, GAQorannoo 42
- Houston, TXQorannoo 38
- Durham, NCQorannoo 37
- Nashville, TNQorannoo 32
- Denver, COQorannoo 27
- Rochester, MNQorannoo 24
- St. Louis, MOQorannoo 24
- Columbus, OHQorannoo 24
- Baldwin Park, CAQorannoo 23
- Edison, NJQorannoo 22
- Chicago, ILQorannoo 22
Qorannoo biroo New York City keessatti
- Saree OljooQorannoo 136
- Kansara Qara'a Non-Small CellQorannoo 121
- Saree (Gosoota Hunda)Qorannoo 109
- Kansarii ProstateQorannoo 103
- Kansara MetastatikiiQorannoo 93
- Kansarii ColorectalQorannoo 78
- Kansarii OvariiQorannoo 69
- Dhibee QaraQorannoo 60
- Kansarii PancreasQorannoo 60
- Kansa EndometiriyaaliiQorannoo 52
- Leukemia Myeloidii HamaaQorannoo 51
- Cufama OnneeQorannoo 51
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.